Your session is about to expire
← Back to Search
Other
Procalcitonin (PCT) group for Bronchitis (ProACT Trial)
N/A
Waitlist Available
Led By David T Huang, MD MPH
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
Summary
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
Eligible Conditions
- Bronchitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Any Adverse Outcome
Total Antibiotic Exposure Days
Secondary outcome measures
Antibiotic Prescription in Emergency Department(ED)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Procalcitonin (PCT) groupExperimental Treatment4 Interventions
Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
Group II: Usual Care groupActive Control1 Intervention
Telephone Visit at Day 15 and Day 30
Find a Location
Who is running the clinical trial?
University of PittsburghLead Sponsor
1,762 Previous Clinical Trials
16,346,339 Total Patients Enrolled
1 Trials studying Bronchitis
3,000 Patients Enrolled for Bronchitis
National Institute of General Medical Sciences (NIGMS)NIH
282 Previous Clinical Trials
246,575 Total Patients Enrolled
BioMérieuxIndustry Sponsor
59 Previous Clinical Trials
41,484 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger